BetterLife FSHD: A Patient-driven Health and Research Platform
Part of paid clinical trials in Randolph, Massachusetts.
- Sponsor
- FSHD Society
- Study ID
- NCT07409142
- Status
- Recruiting
Conditions
- FSH
- FSH Muscular Dystrophy
- FSHD
- FSHD - Facioscapulohumeral Muscular Dystrophy
- FSHD1
- FSHD2
- Facioscapulohumeral Muscular Dystrophy
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Facioscapulohumeral Muscular Dystrophy 1
- Facioscapulohumeral Muscular Dystrophy 2
- Muscular Dystrophy, Facioscapulohumeral
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Year - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Observational — OTHERObservational study
Study Details
BetterLife FSHD is a registry platform built to support people living with FSHD. It connects patients with personalized resources, tools, and research opportunities that match their health experiences and needs. At the same time, BetterLife collects secure health and experience data from patients to support research. This data is shared with researchers to help better understand FSHD and work toward improved care, treatments, and outcomes for the community. Learn more and enroll at: www.BetterLifeFSHD.org
Key Dates
- Start date
- Aug 2, 2024
- Status verified
- Feb 2026
- Primary completion
- Jan 31, 2060
- Completion
- Jan 31, 2060
Study Design
- Enrollment
- 5,000 participants (estimated)
Primary Outcome Measure
Longitudinal Health Data [ Time Frame: Assessed annually from enrollment until study completion (10 years) ]
Central Contacts
- Kayleigh Worek, MS781-301-6060
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| FSHD Society | Randolph | Massachusetts | 02368 |
Find similar trials in Randolph, MA
By research site
Related Studies
- Biomarker Development for Muscular DystrophiesRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyPHASE1/PHASE2 · Recruiting · Epicrispr Biotechnologies, Inc. · Los Angeles, California
- A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDPHASE3 · Recruiting · Avidity Biosciences, Inc. · Orange, California
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy RegistryRecruiting · University of Rochester · Rochester, New York